Botulinum Neurotoxins: opportunities for biosimilars and biosuperiors to capture market shares (2)

STUTTGART, Germany I July 16, 2014 I A new business report entitled „Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders“ has been released by La Merie Publishing. The worldwide market for botulinum neurotoxins has grown with double digit rates over the last years to US$ 2.8 bln in the year 2013 and is expected to reach a size of US$ 4.4 bln in the year 2017. About 54% of the botulinum neutoroxin sales are generated with medical indications, the rest with esthetic indications. The high brand recognition of Botox is one of the factors why Allergan is dominating the global market of botulinum neurotoxins with regional market shares reaching 70-80%. However, patent expiries and the entry of new competitors in the main markets with increasing efforts in development and marketing & sales represents an inflection point in the long-lasting predominance.

Korean companies play an important role in the forthcoming competition as they have specific experience botulinum toxins and have adapted the manufacturing to comply with FDA and EMA guidelines. As a consequence, at least two potential biosimilar versions of botulinum neurotoxin type A are being developed by US and EU companies in partnership with the Korean originators.

As biosimilar products usually go hand in hand with price cuts, the companies with established first generation products are investing in biosuperior product development. Technologies to enable biosuperiors are classical protein formulation to create ready-to-use injectable botulinum toxins, but also more sophisticated pharmaceutical drug delivery technologies to enable, needle- and pain-free transdermal administration. While the first approch may provide advantages for handling of the drug product in the doctor’s office, patients will appreciate topical application of botulinum toxin as a gel, cream or lotion for cosmetic procedures, as market research indicates.

Recombinant DNA technology is also being used to create engineered versions of botulinum toxin which may allow to tap new indications, but also provide a longer-lasting effect with lower side effects in the established indications.

The business report Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders can be acquired at the online store www.pipelinereview.com of La Merie Publishing: http://pipelinereview.com/index.php/therapeuticarea/dermatology/botulinum-neurotoxins-a-comparative-industry-analysis-of-products,-pipelines,-technologies-and-stakeholders-detail

About La Merie Publishing

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.

About PipelineReview.com

PipelineReview.com is the Biologics News Center and Online Store of La Merie Publishing focused on Research and Development in the Biopharmaceutical Industry. The FREE weekly R&D Newletter La Merie Biologics conveniently brings via e-mail a selection of the most interesting biologics news from biopharmaceutical R&D. For more information visit www.pipelinereview.com.

SOURCE: La Merie Publishing